Fosteabine (BioDeep_00000014143)

   


代谢物信息卡片


SCHEMBL13524289

化学式: C27H50N3O8P (575.333535)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCCCCCCCCCCCCCCCCCOP(=O)(O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)O)O
InChI: InChI=1S/C27H50N3O8P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20-36-39(34,35)37-21-22-24(31)25(32)26(38-22)30-19-18-23(28)29-27(30)33/h18-19,22,24-26,31-32H,2-17,20-21H2,1H3,(H,34,35)(H2,28,29,33)/t22-,24-,25+,26-/m1/s1

描述信息

D000970 - Antineoplastic Agents

同义名列表

2 个代谢物同义名

Fosteabine; SCHEMBL13524289



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Akira Horikoshi, Kazuhiro Takei, Yoshifumi Hosokawa, Shigemasa Sawada. The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients. International journal of hematology. 2008 Mar; 87(2):118-125. doi: 10.1007/s12185-007-0019-6. [PMID: 18228114]
  • J Braess, M Freund, A Hanauske, G Heil, C Kaufmann, W Kern, M Schüssler, W Hiddemann, E Schleyer. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. Leukemia. 1998 Oct; 12(10):1618-26. doi: 10.1038/sj.leu.2401152. [PMID: 9766508]
  • Y Ueda, S Mori, T Ito, Y Maesako, H Konishi, Y Yagiri. [A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 1998 May; 39(5):348-54. doi: NULL. [PMID: 9637884]
  • Y Kiyama, G Suzuki, N Masauzi, H Ohizumi, N Kobayashi, M Ogasawara, T Naohara, M Saito, T Higa, M Kasai. [Treatment of refractory hematologic malignancies by combination of cytarabine ocfosfate and etoposide]. Gan to kagaku ryoho. Cancer & chemotherapy. 1996 Oct; 23(12):1717-20. doi: NULL. [PMID: 8886052]
  • E Schleyer, J Braess, B Ramsauer, M Unterhalt, C Kaufmann, S Wilde, M Schüssler, W Hiddemann. Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. Leukemia. 1995 Jun; 9(6):1085-90. doi: . [PMID: 7596174]
  • B Ramsauer, J Braess, M Unterhalt, C C Kaufmann, W Hiddemann, E Schleyer. Highly sensitive high-performance liquid chromatographic assay for 1-beta-D-arabinofuranosylcytosine-5'-stearyl phosphate (cytarabine-ocfosfate). Journal of chromatography. B, Biomedical applications. 1995 Mar; 665(1):183-92. doi: 10.1016/0378-4347(94)00523-8. [PMID: 7795790]
  • H Tsutsumi, T Kumakawa, M Hirai, M Kikukawa, Y Arie, M Mori, H Kodo, N Nakamura, Y Murai, R Mizutani. [Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics. 1995 Mar; 32(3):190-4. doi: 10.3143/geriatrics.32.190. [PMID: 7596061]
  • T Ueda, K Kamiya, Y Urasaki, S Wataya, Y Kawai, H Tsutani, M Sugiyama, T Nakamura. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. Cancer research. 1994 Jan; 54(1):109-13. doi: NULL. [PMID: 8261429]
  • M Higashigawa, D C Cao, K Matsui, S Yamada, H Kakitou, Y Kagawa, H Inamochi, M Ido, M Sakurai. Combined oral administration of etoposide and arabinofuranosylcytosine-5'-stearylphosphate enhances the antitumor effect against P388 ascites tumors. Cancer chemotherapy and pharmacology. 1994; 33(4):281-5. doi: 10.1007/bf00685900. [PMID: 8281619]
  • M Fukuoka, T Miyazaki, Y Yoshida, M Hattori, H Niitani, T Nakamura, Y Hirota, K Ohta, M Tanaka, Y Suzuoki. [Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)]. Gan to kagaku ryoho. Cancer & chemotherapy. 1990 Nov; 17(11):2213-9. doi: NULL. [PMID: 2241185]
  • M Nishikawa, K Morita, F Komada, Y Uemura, S Kageyama, N Minami, K Deguchi, S Shirakawa. [A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)]. Gan no rinsho. Japan journal of cancer clinics. 1990 Oct; 36(12):2204-9. doi: NULL. [PMID: 2232191]
  • M Higashigawa, H Hori, T Ohkubo, H Kawasaki, T Yoshizumi, M Sakurai. Deoxyribonucleoside triphosphate pools and Ara-CTP levels in P388 murine leukemic cells treated with 1-B-D-arabinofuranosylcytosine-5'-stearylphosphate which is a newly synthesized derivative of 1-B-D-arabinofuranosylcytosine. Medical oncology and tumor pharmacotherapy. 1990; 7(4):223-6. doi: 10.1007/bf02987099. [PMID: 2283889]
  • K Kodama, M Morozumi, K Saitoh, A Kuninaka, H Yoshino, M Saneyoshi. Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine. Japanese journal of cancer research : Gann. 1989 Jul; 80(7):679-85. doi: 10.1111/j.1349-7006.1989.tb01696.x. [PMID: 2507491]